*October 2020*
Shirish M. Gadgeel, MD, MBBS, highlights some of the recent targeted therapy advances in NSCLC and how ongoing research is taking the paradigm to the next level.
The molecular landscape of non–small cell lung cancer (NSCLC), especially with EGFR mutations and acquired resistance, continues to get more complex as preliminary data with JNJ-372, higher-dose osimertinib (Tagrisso), and TKI combinations lead to intriguing discussions in the community, explained Shirish M. Gadgeel, MD, MBBS.
Furthermore, with the emergence of targeted therapies, biomarker testing has become a critical aspect of treatment decision making in lung cancer, Gadgeel added.
“There is no one-size-fits-all treatment option for patients with lung cancer, particularly NSCLC,” said Gadgeel. “It’s extremely important that we continue to profile tumors as thoroughly and adequately as possible so that we can initiate optimal courses of therapy.”
In an interview with OncLive® during the 2020 Institutional Perspectives in Cancer webinar on lung cancer, Gadgeel, a Mary Lou Kennedy Research professor in thoracic oncology, professor in the Department of Internal Medicine and the Division of Hematology/Oncology, who is also a co-leader of the Thoracic Oncology Research Program, and an associate director of the Networking and Affiliated Centers at the University of Michigan Medicine, highlighted some of the recent targeted therapy advances in NSCLC and how ongoing research is taking the paradigm to the next level. Read the interview here.
